Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fabry disease
Biotech
4DMT restructures pipeline, extending cash runway through 2028
4DMT is axing two clinical programs and shutting off funds for three other assets, with resources to be pivoted toward gene therapy 4D-150.
Gabrielle Masson
Jan 10, 2025 2:00pm
Sangamo slashes time to market for Fabry gene therapy
Oct 22, 2024 12:57pm
Relay loses interest in SHP2 inhibitor after Genentech leaves
Aug 7, 2024 6:00am
Crosswalk grabs compounds from abandoned Takeda, Codexis collab
Jul 2, 2024 9:55am
Sangamo lays off 27% of US staff in latest refocus
Apr 27, 2023 8:55am
FDA slaps hold on 4DMT's phase 1/2 gene therapy trial
Feb 3, 2023 1:28pm
